Axatilimab

Axatilimab
Monoclonal antibody
TypeWhole antibody
SourceHumanized
TargetCSF-1R
Clinical data
Trade namesNiktimvo
Other namesaxatilimab-csfr
AHFS/Drugs.comNiktimvo
License data
Routes of
administration		Intravenous
Drug classAntineoplastic
ATC code
  • None
Legal status
Legal status
Identifiers
CAS Number
DrugBank
UNII
KEGG
Chemical and physical data
FormulaC6568H10092N1696O2052S48
Molar mass147185.68 g·mol−1

Axatilimab, sold under the brand name Niktimvo, is a monoclonal antibody used for the treatment of chronic graft-versus-host disease.[1] It is a blocker of the colony stimulating factor-1 receptor.[1] It is given by injection into a vein.[1]

Axatilimab was approved for medical use in the United States in August 2024.[1][2]

  1. ^ a b c d e "Niktimvo- axatilimab-csfr injection". DailyMed. 16 August 2024. Retrieved 5 September 2024.
  2. ^ "FDA approves axatilimab-csfr for chronic graft-versus-host disease". U.S. Food and Drug Administration. 14 August 2024. Archived from the original on 15 August 2024. Retrieved 15 August 2024. Public Domain This article incorporates text from this source, which is in the public domain.